Cargando…

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach

Despite tremendous progress being made in recent years, multiple myeloma (MM) remains a challenging disease. The laboratory plays a critical role in the overall management of patients. The diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the clinical care p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ríos-Tamayo, Rafael, Puig, Noemí, Algarín, Macarena, García de Veas Silva, José Luís, Barbosa, Nuno, Encinas, Cristina, Hernández, José Ángel, Alonso, Rafael, Campos, María Luisa, Rodríguez, Teresa, Leivas, Alberto, Olivares, María José, Sánchez, María José, Paiva, Bruno, Lahuerta, Juan José, Martínez-López, Joaquín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620453/ https://www.ncbi.nlm.nih.gov/pubmed/34829367 http://dx.doi.org/10.3390/diagnostics11112020

Ejemplares similares

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
por: Hernández-Rivas, José-Ángel, et al.
Publicado: (2022)

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2022)

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
por: Alonso, Rafael, et al.
Publicado: (2022)

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2016)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients
por: García de Veas Silva, José Luis, et al.
Publicado: (2016)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
por: Garcia de Veas Silva, Jose Luis, et al.
Publicado: (2021)

AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2023)

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
por: Cedena, Maria-Teresa, et al.
Publicado: (2020)

Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2023)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
por: Botta, Cirino, et al.
Publicado: (2023)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma
por: Rodríguez-García, Alba, et al.
Publicado: (2022)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
por: Martínez-López, Joaquín, et al.
Publicado: (2021)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Low field slice-selective ZTE imaging of ultra-short [Formula: see text] tissues based on spin-locking
por: Borreguero, Jose, et al.
Publicado: (2023)

Author Correction: Low field slice-selective ZTE imaging of ultra-short T(2) tissues based on spin-locking
por: Borreguero, Jose, et al.
Publicado: (2023)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
por: Leivas, Alejandra, et al.
Publicado: (2021)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
por: Martínez-López, Joaquín, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
por: Encinas, Cristina, et al.
Publicado: (2022)

Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2023)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
por: Blade, Joan, et al.
Publicado: (2018)

Temperature-Compensated Clock Skew Adjustment
por: Castillo-Secilla, Jose María, et al.
Publicado: (2013)

Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19
por: García-Ríos, Estéfani, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1f2chsr6l1ksj6up0mddes8vqu